

BioCanCell Announces Company Name Change to Anchiano Therapeutics

CAMBRIDGE, Mass., August 27, 2018 — BioCanCell Ltd. (TASE: [ANCN](#)), a clinical-stage biopharmaceutical company focused on the discovery and development of novel therapies to treat cancer, today announced that the company is changing its name to Anchiano Therapeutics. Anchiano Therapeutics remains publicly traded on the Tel Aviv Stock Exchange under the ticker symbol “ANCN” (formerly “BICL”).

“We have undergone a transformation over the last two years, opening our office in Cambridge, bringing our clinical development team aboard, and preparing our pivotal clinical development program for execution in the US and internationally. Our new name, Anchiano Therapeutics, reflects the next stage in our evolution,” said Frank Haluska, M.D., Ph.D., President and Chief Executive Officer of Anchiano Therapeutics. “Anchiano is the birthplace of Leonardo da Vinci. It is our symbolic wellspring of the innovation and artistry in science that lies at the foundation of our commitment to bringing new approaches to the treatment of cancer. The first of these, our experimental gene therapy for early bladder cancer with inodiftagene vixteplasmid, will enter its initial pivotal study, the Codex Trial, later this year.”

About Anchiano Therapeutics

Anchiano Therapeutics is a clinical-stage biopharmaceutical company focused on the discovery and development of novel therapies to treat cancer, with offices in Cambridge, MA, and Jerusalem, Israel. The Company’s most advanced product candidate, inodiftagene vixteplasmid (BC-819), is in development as a treatment for non-muscle invasive bladder cancer. For additional information on inodiftagene vixteplasmid or the Codex Trial please go to <http://www.anchiano.com>.

Forward Looking Statements

This press release contains “forward-looking statements” that are subject to risks and uncertainties. These forward-looking statements include information about possible or assumed future results of clinical trials, the anticipated effects of receiving Fast Track designation, the anticipated timeframe for conducting additional clinical trials and making regulatory submissions, and other strategic and business plans and objectives. These forward-looking statements are based on information Anchiano Therapeutics has when those statements are made or its management’s good faith belief as of that time with respect to future events, and are subject to risks and uncertainties that could cause actual performance or results to differ materially from those expressed in or suggested by the forward-looking statements. These risks and uncertainties include, but are not limited to: the success of the approach to discover and develop prospective therapeutic products, which is new and may never lead to marketable products; a lack of history of commercial sales; a dependence on the success of inodiftagene, the development of which will require significant additional clinical testing before regulatory approval can be sought and commercial sales launched; a need to raise substantial additional funds to complete R&D activities; an ability to overcome scientific or technological difficulties that may be encountered and that may impede R&D activities; and an ability to obtain and maintain intellectual property protection for product candidates, including pursuant to licensed patents.

Company Contact:

Frank Haluska, M.D., Ph.D.
President and Chief Executive Officer
857-259-4622
info@anchiano.com

Investor Contact:

Ashley R. Robinson
Managing Director
LifeSci Advisors, LLC
617-535-7752
arr@lifesciadvisors.com